Celecoxib and ankylosing spondylitis

References

• Brooks PM, Day RO. Non-steroidal anti-inflammatory drugs – differences and similarities. N. Engl. J. Med.324, 1716–1725 (1991).
   PubMed Web of Science ®Google Scholar
• Marnett LJ, Rowlinson SW, Goodwin DC, Kalgutkar AS, Lanzo CA. Arachidonic acid oxygenation by COX-1 and COX-2: mechanisms of catalysis and inhibition. J. Biol. Chem.274, 22903–22906 (1999).
   PubMed Web of Science ®Google Scholar
• Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat. Struct. Biol.2, 637–643 (1995).
   PubMedGoogle Scholar
• Pash JM, Bailey JM. Inhibition by corticosteroids of epidermal growth factor-induced recovery of cyclooxygenase after aspirin inactivation. FASEB J.2, 2613–2618 (1988).
   PubMedGoogle Scholar
• Sebaldt RJ, Sheller JR, Oates JA, Roberts LJ 2nd, FitzGerald GA. Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. Proc. Natl Acad. Sci. USA87, 6974–6978 (1990).
   PubMed Web of Science ®Google Scholar
• Masferrer JL, Zweifel BS, Seibert K, Needleman P. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J. Clin. Invest.86, 1375–1379 (1990).
   PubMed Web of Science ®Google Scholar
• Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl Acad. Sci. USA88, 2692–2696 (1991).
   PubMed Web of Science ®Google Scholar
• Kujubu DA, Herschman HR. Dexamethasone inhibits mitogen induction of the T1S10 prostaglandin synthase/cyclooxygenase gene. J. Biol. Chem.67, 7991–7994 (1992).
   Google Scholar
• O’Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc. Natl Acad. Sci. USA89, 4888–4892 (1992).
   PubMed Web of Science ®Google Scholar
• Lee SH, Soyoola E, Chanmugam P et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J. Biol. Chem.267, 25934–25938 (1992).
   PubMed Web of Science ®Google Scholar
• Sheng H, Shao J, Dixon DA et al. Transforming growth factor-β1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J. Biol. Chem.275, 6628–6635 (2000).
   PubMed Web of Science ®Google Scholar
• Smith CJ, Morrow JD, Roberts LJ II, Marnett LJ. Induction of prostaglandin endoperoxide synthase-1 (COX-1) in a human promonocytic cell line by treatment with the differentiating agent TPA. Adv. Exp. Med. Biol.400, 99–106 (1997).
   Google Scholar
• Rocca B, Spain LM, Pure E, Laugenbach R, Patrono C, FitzGerald GA. Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J. Clin. Invest.103, 1469–1477 (1999).
   PubMed Web of Science ®Google Scholar
• Crofford LJ, Wilder RL, Ristimäki AP et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues: effects of interleukin-1b, phorbol ester, and corticosteroids. J. Clin. Invest.93, 1095–1101 (1994).
   PubMed Web of Science ®Google Scholar
• Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am. J. Pathol.155, 1281–1291 (1999).
   PubMed Web of Science ®Google Scholar
• Kurumbail RG, Stevens AM, Gierse JK et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature384, 644–648 (1996); erratum in Nature385, 555 (1997).
   PubMed Web of Science ®Google Scholar
• Malkowski MG, Ginell SL, Smith WL, Garavito RM. The productive conformation of arachidonic acid bound to prostaglandin synthase. Science289, 1933–1937 (2000).
   PubMed Web of Science ®Google Scholar
• Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mithcell JA, Vane JR. Non-steroid drug selectives for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl Acad. Sci. USA96, 7563–7568 (1999); erratum in Proc. Natl Acad. Sci. USA96, 9666 (1999).
   PubMed Web of Science ®Google Scholar
• Cryer B, Feldman M. Cyclo-oxygenase-1 and cyclo-oxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am. J. Med.104, 413–421 (1998).
   PubMed Web of Science ®Google Scholar
• Patrono C, Ciabattoni G, Pinca E et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb. Res.17, 317–327 (1980).
   PubMed Web of Science ®Google Scholar
• Patrignani P, Panara MR, Greco A et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J. Pharmacol. Exp. Ther.271, 1705–1712 (1994).
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA284, 1247–1255 (2000).
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med.343, 1520–1528 (2000).
   PubMed Web of Science ®Google Scholar
• Patrignani P, Panara MR, Sciulli MG, Santini G, Renda G, Patrono C. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J. Physiol. Pharmacol.48, 623–631 (1997).
   PubMed Web of Science ®Google Scholar
• Chan C-C, Boyes S, Brideau C et al. Rofecoxib [Vioxx, MK-0966; 4-(4´-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor: pharmacological and biochemical profiles. J. Pharmacol. Exp. Ther.290, 551–560 (1999).
   PubMed Web of Science ®Google Scholar
• Tang C, Shou M, Mei Q, Rushmore TH, Rodrigues AD. Major role in human liver microsomal cytochrome P450 2C9 (CYP2C90) in the oxidative metabolism of celecoxib, a novel cyclo-oxygenase-II inhibitor. J. Pharmacol. Exp. Ther.293, 453–459 (2000).
   PubMed Web of Science ®Google Scholar
• Davies NM, McLachlan AD, Day RO, Williams KM. Clnical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenas-2 inhibitor. Clin. Pharmacokinet.38, 225–242 (2000).
   PubMed Web of Science ®Google Scholar
• Paulson SK, Hribar JD, Liu NW et al. Metabolism and excretion of [14C]celecoxib in healthy male volunteers. Drug Metab. Dispos.28, 308–314 (2000).
   PubMed Web of Science ®Google Scholar
• Karim A, Tolbert DS, Hunt TL, Hubbard RC, Harper KM, Geis GS. Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J. Rheumatol.26, 2539–2543 (1999).
   PubMed Web of Science ®Google Scholar
• Porras A, Ko A, Larson P et al. Single and multiple dose pharmacokinetics (PK) of rofecoxib (R) in healthy subjects. Clin. Pharmacol. Ther.67, 137–137 (2000) (Abstract).
   Google Scholar
• Depre M, Ehrich E, Van Hecken A et al. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. Eur. J. Clin. Pharmacol.56, 167–174 (2000).
   PubMed Web of Science ®Google Scholar
• Schwartz J, Zhao P, Gertz B et al. Pharmacokinetics of rofecoxib in mild to moderate hepatic insufficiency (H1). Clin. Pharmacol. Ther.67, 137–137 (2000) (Abstract).
   Google Scholar
• Schwartz JI, Larson PJ, Bugianesi KJ et al. Effect of rofecoxib (R) on the pharmacodynamics and pharmacokinetics (PK) of warfarin (W). Clin. Pharmacol. Ther.67, 165–165 (2000) (Abstract).
   Google Scholar
• Nicoll-Griffith DA, Yergey JA, Trimble LA et al. Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx). Bioorg. Med. Chem. Lett.10, 2683–2686 (2000).
   PubMed Web of Science ®Google Scholar
• Hawkey C, Laine L, Simon T et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum.43, 370–377 (2000).
   PubMed Web of Science ®Google Scholar
• Simon LS, Lanza FL, Lipsky PE et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum.41, 1591–1602 (1998).
   PubMed Web of Science ®Google Scholar
• Bensen WG, Fiechtner JJ, McMillen JI et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin. Proc.74, 1095–1105 (1999).
   PubMed Web of Science ®Google Scholar
• Clemett D, Goa KL. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs59, 957–980 (2000).
   PubMed Web of Science ®Google Scholar
• Cannon GW, Caldwell JR, Holt P et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum.43, 978–987 (2000).
   PubMed Web of Science ®Google Scholar
• Day R, Morrison B, Luza A et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch. Intern. Med.160, 1781–1787 (2000).
   PubMed Web of Science ®Google Scholar
• Simon LS, Weaver AL, Graham DY et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA282, 1921–1928 (1999).
   PubMed Web of Science ®Google Scholar
• McAdam BF, Mardini I, Habib A et al. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J. Clin. Invest.105, 1473–1482 (2000).
   PubMed Web of Science ®Google Scholar
• Seibert K, Zhang Y, Leahy K et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl Acad. Sci. USA91, 12013–12017 (1994).
   PubMed Web of Science ®Google Scholar
• Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med.5, 698–701 (1999).
   PubMed Web of Science ®Google Scholar
• Langman MJ, Jensen DM, Watson DJ et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA282, 1929–1933 (1999).
   PubMed Web of Science ®Google Scholar
• Silverstein FD, Graham DY, Senior JR et al. Misoprostol reduced serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med.123, 241–249 (1995).
   PubMed Web of Science ®Google Scholar
• Zimmermann KC, Sarbia M, Schror K, Weber AA. Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol. Pharmacol.54, 536–540 (1998).
   PubMed Web of Science ®Google Scholar
• Sawaoka H, Kawano S, Tsuji S et al. Helicobacter pylori infection induces cyclooxygenase-2 expression in human gastric mucosa. Prostaglandins Leukot. Essent. Fatty Acids59, 313–316 (1998).
   PubMed Web of Science ®Google Scholar
• McCarthy CJ, Crofford LJ, Greenson J, Scheiman JM. Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection. Am. J. Gastroenterol.94, 1218–1223 (1999).
   PubMed Web of Science ®Google Scholar
• Mizuno H, Sakamoto C, Matsuda K et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology112, 387–397 (1997).
   PubMed Web of Science ®Google Scholar
• Prescott SM. Is cyclooxygenase-2 the a and the w in cancer? J.Clin. Invest.105, 1511–1513 (2000).
   PubMedGoogle Scholar
• Newberry RD, Stenson WF, Lorenz RG. Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen. Nat. Med.5, 900–906 (1999).
   PubMed Web of Science ®Google Scholar
• Morteau O, Morham SG, Sellon R et al. Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J. Clin. Invest.105, 469–478 (2000).
   PubMedGoogle Scholar
• Reuter BK, Asfaha S, Buret A, Sharkey KA, Wallace JL. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J. Clin. Invest.98, 2076–2085 (1996).
   PubMed Web of Science ®Google Scholar
• FitzGerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N. Engl. J. Med.310(17), 1065–1068 (1984).
   PubMed Web of Science ®Google Scholar
• McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl Acad. Sci. USA96, 272–277(1999); erratum in Proc. Natl Acad. Sci. USA96, 5890 (1999).
   PubMed Web of Science ®Google Scholar
• Cullen L, Kelly L, Connor SO, Fitzgerald DJ. Selective cyclooxygenase-2 inhibition by nimesulide in man. J. Pharmacol. Exp. Ther.287, 578–582 (1998).
   PubMed Web of Science ®Google Scholar
• Catella-Lawson F, McAdam B, Morrison BW et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J. Pharmacol. Exp. Ther.289, 735–741 (1999).
   PubMed Web of Science ®Google Scholar
• FitzGerald GA, Brash AR, Falardeau P, Oates JA. Estimated rate of prostacyclin secretion into the circulation of normal man. J. Clin. Invest.68, 1272–1275 (1981).
   PubMed Web of Science ®Google Scholar
• Braden GA, Knapp HR, FitzGerald GA. Suppression of eicosanoid biosynthesis during coronary angioplasty by fish oil and aspirin. Circulation84, 679–685 (1991).
   PubMedGoogle Scholar
• Wennmalm A, FitzGerald GA. Excretion of prostacyclin and thromboxane A2 metabolites during leg exercise in humans. Am. J. Physiol.255, H15–H18 (1988).
   Google Scholar
• Topper JN, Cai J, Falb D, Gimbrone MA Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc. Natl Acad. Sci. USA93, 10417–10422 (1996).
   PubMed Web of Science ®Google Scholar
• Murata T, Ushikubi F, Matsuoka T et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature388, 678–682 (1997).
   PubMed Web of Science ®Google Scholar
• Crofford LJ, Oates JC, McCune WJ et al. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors: a report of four cases. Arthritis Rheum.43, 1891–1896 (2000).
   PubMed Web of Science ®Google Scholar
• Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in northern Sweden. J. Rheumatol.24, 445–451 (1997).
   PubMed Web of Science ®Google Scholar
• Wallberg-Jonsson S, Cederfelt M, Rantapää Dahlqvist S. Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year followup study. J. Rheumatol.27, 71–75 (2000).
   PubMedGoogle Scholar
• Van Hecken A, Schwartz JI, Depre M et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J. Clin. Pharmacol.40, 1109–1120 (2000).
   PubMed Web of Science ®Google Scholar
• Knijff-Dutmer EA, Martens A, vd Laar MA. Effects of nabumetone compared with naproxen on platelet aggregation in patients with rheumatoid arthritis. Ann. Rheum. Dis.58, 257–259 (1999).
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and nonaspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology11, 382–387 (2000).
   PubMedGoogle Scholar
• Pratico D. Tillman C, Zhang ZB, Li H, FitzGerald GA. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc. Natl Acad. Sci. USA98, 3358–3363 (2001).
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ (ATT) Collaboration. Prevention of death, myocardial infarction and stroke by antiplatelet therapy: collaborative meta-analysis of 266 trials involving 200,000 patients at high risk of occlusive vascular events. Br. Med. J.325, 71–86 (2008).
   Google Scholar
• Patrono C, Coller B, Dalen JE et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest119(Suppl.), 39S–63S (2001).
   PubMed Web of Science ®Google Scholar
• Adderley SR, Fitzgerald DJ. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J. Biol. Chem.274, 5038–5046 (1999).
   PubMed Web of Science ®Google Scholar
• Shinmura K, Tang XL, Wang Y et al. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc. Natl Acad. Sci. USA97, 10197–10202 (2000).
   PubMed Web of Science ®Google Scholar
• Strand V. Are Cox-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet370(9605), 2138–2151 (2007).
   PubMed Web of Science ®Google Scholar
• Dinchuk JE, Car BD, Focht RJ et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature378, 406–409 (1995).
   PubMed Web of Science ®Google Scholar
• Komhoff M, Wang JL, Cheng HF et al. Cyclooxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development. Kidney Int.57, 414–422 (2000).
   PubMed Web of Science ®Google Scholar
• Nantel F, Meadows E, Denis D, Connolly B, Metters KM, Giaid A. Immunolocalization of cyclooxygenase 2 in the macula densa of human elderly. FEBS Lett.457, 475–477 (1999).
   PubMed Web of Science ®Google Scholar
• Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int.32, 1–12 (1987).
   PubMed Web of Science ®Google Scholar
• Swan SK, Rudy DW, Lasseter KC et al. Randomized evaluations of the effects of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: a randomized, controlled trial. Ann. Intern. Med.133, 1–9 (2000).
   PubMed Web of Science ®Google Scholar
• Whelton A, Maurath CJ, Verburg KM, Geis GS. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am. J. Ther.7, 159–175 (2000).
   PubMedGoogle Scholar
• Whelton A. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2 specific inhibitors. Am. J. Med.110(Suppl. 1) 33–42 (2001).
   PubMed Web of Science ®Google Scholar
• Scott PA, Kingsley GH, Smith CM, Choy EH, Scott DL. Non-steroidal anti-inflammatory drugs and myocardial infactions: comparative systemic review of evidence from observational studies and randomised controlled trials. Ann. Rheum. Dis.66, 1296–1304 (2007).
   PubMed Web of Science ®Google Scholar
• Panara MR, Padovano R, Sciulli MG et al. Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings. Clin. Pharmacol. Ther.63, 672–681 (1998).
   PubMed Web of Science ®Google Scholar
• Tegeder I, Lotsch J, Krebs S, Muth-Selbach U, Brune K, Geisslinger G. Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state. Clin. Pharmacol. Ther.65, 533–544 (1999).
   PubMed Web of Science ®Google Scholar
• Feldman M, McMahon AT. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann. Intern. Med.132, 134–143 (2000); erratum in Ann. Intern. Med.132, 1011 (2000).
   PubMed Web of Science ®Google Scholar
• Singla AK, Chawla M, Singh A. Nimesulide: some pharmaceutical and pharmacological aspects – an update. J. Pharm. Pharmacol.52, 467–486 (2000).
   PubMed Web of Science ®Google Scholar
• Shah AA, Thjodleifsson B, Murray FE et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut48, 339–346 (2001).
   PubMed Web of Science ®Google Scholar
• Porto A, Almeida H, Cunha MJ, Macciocchi A. Double-blind study gastric mucosa in osteoarthritic patients. Eur. J. Rheumatol. Inflamm.14, 33–38 (1994).
   PubMedGoogle Scholar
• Bourgeois P, Dreiser RL, Lequesne MG, Macciocchi A, Monti T. Multi-centre double-blind study to define the most favourable dose of nimesulide in terms of efficacy/safety ratio in the treatment of osteoarthritis. Eur. J. Rheumatol. Inflamm.14, 39–50 (1994).
   PubMedGoogle Scholar
• Hawkey C, Kahan A, Steinbruck K et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br. J. Rheumatol.37, 937–945 (1998); erratum in Br. J. Rheumatol.37, 1142 (1998).
   PubMedGoogle Scholar
• Dequeker J, Hawkey C, Kahan A et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of COX-inhibiting therapies (SELECT) trial in osteoarthritis. Br. J. Rheumatol.37, 946–951 (1998).
   PubMedGoogle Scholar
• Schoenfeld P. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am. J. Med.107, 48S–54S (1999).
   PubMedGoogle Scholar
• Calin A. The Margaret Holroyd Essay (BSR). The individual with ankylosing spondylitis: defining disease status and the impact of the illness. Br. J. Rheumatol.34(7), 663–672 (1995).
   PubMedGoogle Scholar
• Calin A, Taurog J (Eds). The Spondylarthritides. Oxford University Press, Oxford, UK 1–353 (1998).
   Google Scholar
• Jenkinson T, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis: The Bath Ankylosing Spondylitis Metrology Index (BASMI). J. Rheumatol.21, 1694–1698 (1994).
   PubMed Web of Science ®Google Scholar
• Calin A, Garrett SL, Whitelock HC et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index (BASFI). J. Rheumatol.21, 2281–2285 (1994).
   PubMed Web of Science ®Google Scholar
• Garrett SL, Jenkinson TR, Whitelock HC, Kennedy LG, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). J. Rheumatol.21, 2286–2291 (1994).
   PubMed Web of Science ®Google Scholar
• Sieper J, Klopsch T, Richter M et al. Comparison of 2 different dosages of celecoxib with diclofenac for the treatment if active ankylosing spondylitis: results of a 12-week randomised double-blind controlled study. J. Rheumatol.33, 1805–1812 (2006).
   PubMedGoogle Scholar
• Dougados M, Béhier JM, Calin A et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal anti-inflammatory drug. J. Rheumatology33, 1805–1812 (2006).
   PubMedGoogle Scholar
• van der Heijde D, Baraf HS, Calin A et al. Evaluation of the efficacy of celicoxib in ankylosing spondylitis results of a 52 week randomised control study. Arthritis Rheum.52(4), 1205 (2005).
   PubMed Web of Science ®Google Scholar